It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Cyclization provides a general strategy for improving the proteolytic stability, cell membrane permeability and target binding affinity of peptides. Insertion of a stable, non-reducible linker into a disulphide bond is a commonly used approach for cyclizing phage-displayed peptides. However, among the vast collection of cysteine reactive linkers available, few provide the selectivity required to target specific cysteine residues within the peptide in the phage display system, whilst sparing those on the phage capsid. Here, we report the development of a cyclopropenone-based proximity-driven chemical linker that can efficiently cyclize synthetic peptides and peptides fused to a phage-coat protein, and cyclize phage-displayed peptides in a site-specific manner, with no disruption to phage infectivity. Our cyclization strategy enables the construction of stable, highly diverse phage display libraries. These libraries can be used for the selection of high-affinity cyclic peptide binders, as exemplified through model selections on streptavidin and the therapeutic target αvβ3.
Cyclization provides a general strategy for improving peptide proteolytic stability, cell membrane permeability and target binding affinity. Here the authors develop a cyclopropenone-based proximity-driven chemical linker for the site-specific cyclization of phage-displayed peptides.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details






1 University of Cambridge, Yusuf Hamied Department of Chemistry, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000 0001 2188 5934); The Discovery Centre; Cambridge Biomedical Campus, Biologics Engineering, Oncology R&D, AstraZeneca, Cambridge, UK (GRID:grid.5335.0)
2 University of Cambridge, Yusuf Hamied Department of Chemistry, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000 0001 2188 5934)
3 Universidade de Lisboa, Instituto de Investigação do Medicamento (iMed), Faculdade de Farmácia, Lisboa, Portugal (GRID:grid.9983.b) (ISNI:0000 0001 2181 4263)
4 The Discovery Centre; Cambridge Biomedical Campus, Biologics Engineering, Oncology R&D, AstraZeneca, Cambridge, UK (GRID:grid.9983.b)
5 The Discovery Centre; Cambridge Biomedical Campus, Biologics Engineering, Oncology R&D, AstraZeneca, Cambridge, UK (GRID:grid.5335.0)
6 The Discovery Centre; Cambridge Biomedical Campus, Biologics Engineering, Oncology R&D, AstraZeneca, Cambridge, UK (GRID:grid.5335.0); Department of Biotherapeutic Discovery, H. Lundbeck A/S, Valby, Denmark (GRID:grid.424580.f) (ISNI:0000 0004 0476 7612)
7 The Discovery Centre; Cambridge Biomedical Campus, Biologics Engineering, Oncology R&D, AstraZeneca, Cambridge, UK (GRID:grid.424580.f)
8 University of Cambridge, Yusuf Hamied Department of Chemistry, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000 0001 2188 5934); Faculdade de Medicina da Universidade de Lisboa, Instituto de Medicina Molecular João Lobo Antunes, Lisboa, Portugal (GRID:grid.5335.0)